AstraZeneca (NASDAQ:AZN) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

AstraZeneca (NASDAQ:AZN) released its quarterly earnings data on Thursday. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05), Zacks reports. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%.

AstraZeneca Stock Performance

Shares of AZN stock traded up $2.44 during trading hours on Thursday, reaching $73.38. The stock had a trading volume of 5,428,889 shares, compared to its average volume of 4,970,766. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The firm has a 50-day simple moving average of $67.27 and a 200-day simple moving average of $73.70. The firm has a market capitalization of $227.56 billion, a PE ratio of 35.12, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of analyst reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.